Netscientific Share Discussion Threads

[blakieboy7] 19/7/2023 20:28

PDSB up over 4% again

[blakieboy7] 19/7/2023 18:27

We shouldn't need Simon to tell the market how undervalued NSCI is ffs

[loafofbread] 18/7/2023 21:08

Well that's a £1M gain to NSCI in 2 days and hardly one trade.

[blakieboy7] 18/7/2023 08:16

It makes no sense Loaf!

[loafofbread] 18/7/2023 08:13

You would think a £650K gain on one of your investments might be worth a few pence.

The UK market is just pointless.

[blakieboy7] 17/7/2023 16:03

PDSB 10% up now. Expect some movement here soon

[blakieboy7] 17/7/2023 15:04

PDSB up over 6% so far today

[loafofbread] 09/7/2023 17:46

EMV Capital led the completion of £3.2m investment round for Vortex Biosciences to support its next phase of growth in the multi-billion dollar oncology liquid biopsy market. Vortex is now undergoing a technical feasibility study using clinical samples to develop a reliable workflow for enumerating and characterising Circulating Tumour Cells with a US-based biospecimen CRO, MT Group. This will lead on to a clinical observational study that will help position Vortex with key biopharma customers.


Q-Bot, a leading UK robotics company in the building retrofit space, is experiencing significant revenue growth with a continuation of record-breaking months, driven by growing public and private sector market demand, operational efficiency, and improved robot reliability. The company's commercial development is progressing at pace with recent partners including the housing group Plus Dane Housing and Watford Borough Council. The company is actively working on expanding internationally in the EU and US through partnerships, including operations now in France and the Netherlands.


Sofant, the University of Edinburgh spin-out developing satellite and 5G antenna platforms, has announced a joint development with Inmarsat Government aimed at revolutionising the communication capabilities of aircraft. Sofant is currently building its first fully integrated satellite communications terminal, representing the most significant technical milestone in the company's history and a major value inflection point in the path to commercialisation. Designed to meet SES specifications, it will enable the company to achieve its second major milestone for the €7.2M European Space Agency contract.


Following its commercial launch in the UK, SageTech Medical, the sustainable anaesthesia provider, has achieved several significant commercial milestones, including distribution agreement with Dräger UK, Manchester University NHS Trust purchase and winning its first NHS Tender. The company's efficiency has also been confirmed by the internationally renowed Guy's and St Thomas'​ NHS Foundation Trust, concluding that its SID-Dock capture system has high baseline efficiency of 94.8%. The anaesthetic gas capture machine is now available through NHS Supply Chain.


EMV Capital syndicated new investment for NetScientific PLC portfolio company Glycotest, a liver disease diagnostics specialist based in Philadelphia, USA. The $1m third party fundraise is intended to provide Glycotest with further capital to progress development, prepare for market launch in the US, and explore wider market opportunities. Glycotest is pioneering the commercialisation of exclusive blood tests for the detection of life-threatening liver cancers and fibrosis-cirrhosis, which is well aligned with EMV Capital's practice and investments in the field of oncology.


EMV Capital led the completion of a £500,000 investment round in its genetic analysis portfolio company DName-iT, a KU Leuven spin-out, to accelerate further industry pilots, validating its technology and commercial strategy prior to product launch and commercial sales. DName-iT is looking to support the Laboratories industry, which is under increasing pressure to deliver accurate Next Generation Sequencing (NGS) testing for eligibility for novel oncology treatments and other critical advances in personalised medicine.


EpiBone, the first and only biotechnology company to gain FDA approval for human trials for a stemcell-based tissue product, has made significant progress in biphasic bone and cartilage graft development. The company has completed pivotal equine and canine studies, with very positive feedback from its preclinical work. EpiBone is now working towards IND approval for its osteochondral graft product, as well as the completion of clinical studies for its bone graft product.


ProAxis, the commercial medtech company with a focus on respiratory diagnostics, has secured a £500,000 funding facility from AB Group, advised by EMV Capital. ProAxsis has also started a collaboration with our portfolio company Wanda Health to deliver a digitally enabled COPD diagnostic platform.


Wanda Health, the remote patient monitoring (RPM) solution for primary care patients, continues its commercial expansion in the US. The company is working towards securing regulatory position as an FDA-approved device, as well as achieving UKCA and CE Marks which allow for the platform to be sold in the UK and the EU respectively. The company which is dually based in the UK and US also continues development of AI modules and expansion of disease-monitoring programs. In the upcoming month, Wanda plans to launch a seed funding round to support its growth objectives.


Martlet Capital, the Cambridge based early-stage investor, participated in $7.5m Pre-Series A funding for PharmEnable, which has developed a proprietary drug discovery platform, and $2.1m investment round for RoboK, which uses AI to analyse security footage for incidents in real-time. EMV Capital is an investor in Martlet Capital and continues working with the Martlet team to identify scale-up opportunities for IP rich, high growth potential start-ups in the Cambridge ecosystem.


In December 2022, Deeptech Recycling Technologies, in which we hold a 30% direct stake, acquired the majority of assets of Recycling Technologies (a business that had targeted an AIM IPO in Q1 of 2022). EMV Capital’s value creation services team is working on a relaunch of the technology platform for upcycling post-consumer packaging with advanced, environmentally sound technologies company into the rapidly growing plastics waste management space.

[loafofbread] 09/7/2023 09:46

From memory you can sign up to it on the EMV or NSCI website. Also NSCI/EMV has a list of all our companies with a link to their websites. Quite a few of the individual companies have a newsletter you can sign up to. To be fair not all actually send them out but a few do.

[blakieboy7] 09/7/2023 03:58

How did you come across the newsletter Loaf?

[loafofbread] 03/7/2023 07:59

Yup.

20k and 16k buys.

Also Ed Hooper has taken another 40K in shares rather than cash so another effective buy.

Lastly, the options are set at 63p which again is fair as they are only in the money when the share price goes up.

Onward and upward!

[loafofbread] 01/7/2023 19:54

Market cap after Fridays announcement is approx £100M.

Glycotest is going for the liver test but same sized market.

The market values our Glycotest investment at zero but with (delayed)results by year end you can see what could happen.


Renalytix plc
("Renalytix" or the "Company")
FDA Approves KidneyIntelX.dkd(TM)
FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease
LONDON and SALT LAKE CITY, June 30, 2023 - Renalytix plc (LSE: RENX) (NASDAQ:RNLX) announces that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization for its KidneyIntelX.dkd(TM) prognostic test. This affirms KidneyIntelX as a first-in-class, artificial intelligence enabled prognostic testing platform to guide care management for adults with type 2 diabetes and early-stage chronic (diabetic) kidney disease. Renalytix believes FDA authorization will lead to increasing test adoption, informing clinical guidelines, expanding insurance coverage, and pursuing additional international regulatory approvals.
" Meeting the rigorous safety, clinical and analytical validation, and scientific data requirements of an FDA review, from Breakthrough Device designation to De Novo marketing authorization, is a landmark event for health care providers and patients with diabetic kidney disease," said James McCullough, CEO of Renalytix. "With this approval, a new class, Prognostic Test for Assessment of Chronic Kidney Disease Progression, has been established by the FDA, providing a roadmap for future expansion of KidneyIntelX into new indications and products."
KidneyIntelX.dkd accurately stratifies patients into three risk levels (low, moderate, and high). This result provides comprehensive information on patient risk for progressive decline in kidney function within five years, independently of the current standard of care measures. KidneyIntelX.dkd is the name used to differentiate tests to be provided under the De Novo marketing authorization by the FDA from those provided under the KidneyIntelX name as a Laboratory Developed Test.
Since being introduced as a Laboratory Developed Test (LDT), KidneyIntelX results have been reported on approximately 10,000 patients in the United States and there has been broad insurance payment including from Medicare and many private payers.
The KidneyIntelX platform combines blood-based biomarkers with clinical variables using an artificial intelligence enabled algorithm, providing reliable and actionable information to guide care in large, at-risk patient populations. KidneyIntelX is based on technology developed at the Icahn School of Medicine at Mount Sinai in New York, NY, and licensed to Renalytix.

[loafofbread] 01/7/2023 13:51

My money is on a few more director buys.

[blakieboy7] 30/6/2023 11:59

Rights where's Simon Thompson?!

[kingston78] 30/6/2023 10:25

Most of us are losing patience not because of lack of progress by the company but for the stagnation or regression of the share price. There is a big disconnect between the value and increasing accretion of value and the share price.

The beauty of the company's corporate plan is to get external funding for its portfolio companies and to enhance their value at a higher subscription price. There will be crystallisation of gains in cash terms one of these days. The share price will explode once this happens.

[blakieboy7] 30/6/2023 08:35

Ignored by the market - again!

[loafofbread] 30/6/2023 08:34

Another great RNS.

Real world value has gone from £0.1M in the fair value results to £0.8M, backed by one of the worlds biggest funds.

£0.7M gain and on track to sales and expansion so can probably double that again by year end.

[blakieboy7] 28/6/2023 16:27

FFS this goes from bad to worse

[loafofbread] 28/6/2023 13:07

God knows.

Just bought 10K that is yet to show.

AGM tomorrow so maybe a chance of a bit of life?

[blakieboy7] 28/6/2023 10:33

This share price is manipulated to F

[kingston78] 28/6/2023 09:27

Market makers have just marked down the share price by 1.5 p when there are no trades at all. How ridiculous of them just to widen the spread to 5 p!

[kingston78] 22/6/2023 16:25

loafofbread, we are living in a weird world. I have seen so many unworthy shares and yet they double or treble on speculation even though they lose tons of money with unproven business case. Here we are with a wonderful share in NSCI but is apparently not appreciated by many investors.

Trust me, if this trend continues, one day we will find that there is more cash in NSCI than its market capitalisation.